EurekaMag.com logo
+ Site Statistics
References:
47,893,527
Abstracts:
28,296,643
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Trial to side effects compliance and response of 5 aminosalicylic acid mesalazine during the treatment of ulcerative colitis and crohn's disease






Leber Magen Darm 18(2): 104, 106-108, 111-113

Trial to side effects compliance and response of 5 aminosalicylic acid mesalazine during the treatment of ulcerative colitis and crohn's disease

In an open clinical trial 71 patients with ulcerative colitis and 27 patients with Crohn's disease were treated with mesalazine (5-ASA). After four to eight weeks of acute phase treatment, maintenance therapy was ensued by treatment over a period of maximal 48 weeks. The activity of both inflammatory bowel diseases clearly decreased. Relapse was not observed during maintenance treatment in ulcerative colitis. Pathological changes of clincial findings were not observed during treatment. Pathologic changes before treatment, which were associated with the disease, returned to normal during treatment. All potential side effects during treatment were recorded. The rate of side effects was low and all normalized when therapy was continued. The study confirms that mesalazine was safe, efficient and almost well tolerated.


Accession: 006840592



Related references

Bayerdörffer, E.; Bock, H., 1988: Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease. In an open clinical trial 71 patients with ulcerative colitis and 27 patients with Crohn's disease were treated with mesalazine (5-ASA). After four to eight weeks of acute phase treatment, maintenance therapy was ensued by treatment over a pe...

Rachmilewitz, D., 1989: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. To assess the safety and efficacy of a preparation of mesalazine (5-aminosalicylic acid) coated with a pH dependent resin (Eudragit L) as compared with sulphasalazine in patients with active mild to moderate ulcerative colitis. Eight week randomis...

Raedler, A.; Behrens, C.; Bias, P., 2004: Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis - results from a randomized-controlled trial. Background: Formulations containing 5-aminosalicylic acid, such as mesalazine, are the gold standard of treatment for mild-to-moderate ulcerative colitis. Current oral regimens require the use of large tablets and frequent dosing to reach the reco...

Moum, Børn., 2004: 5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease. Ulcerative colitis and Cohn's disease are characterised by exacerbations and remissions. Their aetiology is not known and treatment modalities are therefore focused on the inflammation. A review is given of the literature on the clinical effi...

Campieri, M.; Lanfranchi, G.A.; Bertoni, F.; Brignola, C.; Bazzocchi, G.; Minguzzi, M.R.; Labò, G., 1984: A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. 5-Aminosalicylic acid (5-ASA) is the active component of Salazopyrin and induces a prompt and excellent improvement, when administered as high dosage enema, in patients suffering from active ulcerative colitis. However, the high instability of thi...

Rachmilewitz D.; E.A., 1989: Coated mesalazine 5 aminosalicylic acid versus sulfasalazine in the treatment of active ulcerative colitis a randomized trail. Objective-To assess the safety and efficacy of a preparation of mesalazine (5-aminosalicylic acid) coated with a pH dependent resin (Eudragit L) as compared with sulphasalazine in patients with active mild to moderate ulcerative colitis. Design-Ei...

Harris, M.S.; Lichtenstein, G.R., 2011: Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. The use of topical therapy in the treatment of ulcerative colitis has declined in recent years despite evidence of good efficacy. To review US prescription trends for 5-aminosalicylic acid (5-ASA) since the US approval of Asacol extended-release o...

Riley, S.A.; Mani, V.; Goodman, M.J.; Herd, M.E.; Dutt, S.; Turnberg, L.A., 1988: Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. To assess the safety and efficacy of delayed-release mesalazine (5-aminosalicylic acid) as maintenance treatment for patients with ulcerative colitis, 100 patients with quiescent colitis were randomly grouped to receive either delayed-release mesa...

Paoluzi, P.; D'Albasio, G.; Pera, A.; Bianchi Porro, G.; Paoluzi, O.A.; Pica, R.; Cottone, M.; Miglioli, M.; Prantera, C.; Sturniolo, G.; Ardizzone, S., 2003: Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. The association of oral 5-aminosalicylic acid (mesalazine) and enema is effective in treatment of mild-moderate forms of ulcerative colitis. However no study has been aimed at determining optimal duration of this association in active ulcerative c...

Paoluzi, P.; D'albasio, G.; Pera, A.; Porro, G.B.anchi; Paoluzi, O.A.; Pica, R.; Cottone, M.; Miglioli, M.; Prantera, C.; Sturniolo, G.; Ardizzone, S., 2002: Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: One-year randomised multicentre trial. Background: The association of oral 5-aminosalicylic acid (mesalazine) and enema is effective in treatment of mild-moderate forms of ulcerative colitis. However, no study has been aimed at determining optimal duration of this association in active...